Form 4: Iovance Biotherapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 6, 2026.
Summary
- Option exercise/conversion: acquired 49,995 Common Stock on August 6, 2026; holds 49,995 after (Direct).
- Tax/exercise-price withholding: disposed of 21,238 Common Stock at $6.21 ($131,888) on August 6, 2026; holds 28,757 after (Direct).
- Option exercise/conversion: disposed of 49,995 Restricted Stock Units on August 6, 2026; holds 100,005 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Corleen M. Roche — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-06 | Option exercise/conversion | Common Stock | 49,995 | — | — | 49,995 |
| 2026-08-06 | Tax/exercise-price withholding | Common Stock | 21,238 | $6 | $131.9K | 28,757 |
| 2026-08-06 | Option exercise/conversion | Restricted Stock Units | 49,995 | — | — | 100,005 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-06 | Option exercise/conversion (49,995 shares) |
| 2026-08-06 | Tax/exercise-price withholding (21,238 shares) |
| 2026-08-06 | Option exercise/conversion (49,995 shares) |
Keywords
insider transaction, Form 4, IOVA, IOVANCE BIOTHERAPEUTICS, INC., neutral, Corleen M. Roche
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.